Intellia Therapeutics (NASDAQ:NTLA) Given New $88.00 Price Target at Chardan Capital

Chardan Capital cut their target price on shares of Intellia Therapeutics from $94.00 to $88.00 and set a "buy" rating on the stock in a research note on Thursday." /
Read more...